Kurv Yield Premium Strategy Tesla (TSLA) ETF (TSLP)

BATS: TSLP · Real-Time Price · USD
32.16
+0.95 (3.04%)
At close: Dec 24, 2024, 12:50 PM
32.37
+0.21 (0.66%)
After-hours: Dec 24, 2024, 5:00 PM EST
3.04%
Assets $7.27M
Expense Ratio 1.00%
PE Ratio n/a
Shares Out 290,000
Dividend (ttm) $5.97
Dividend Yield 18.57%
Ex-Dividend Date Nov 20, 2024
Payout Ratio n/a
1-Year Return +12.68%
Volume 8,288
Open 31.53
Previous Close 32.47
Day's Range 31.53 - 32.41
52-Week Low 16.17
52-Week High 34.29
Beta n/a
Holdings 9
Inception Date Oct 27, 2023

About TSLP

Fund Home Page

The Kurv Yield Premium Strategy Tesla (TSLA) ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.

Asset Class Equity
Category Derivative Income
Region North America
Stock Exchange BATS
Ticker Symbol TSLP
ETF Provider Kurv

Dividends

Ex-Dividend Amount Pay Date
Nov 20, 2024 $0.594 Nov 21, 2024
Oct 23, 2024 $0.493 Oct 24, 2024
Sep 25, 2024 $0.516 Sep 26, 2024
Aug 21, 2024 $0.511 Aug 22, 2024
Jul 24, 2024 $0.499 Jul 25, 2024
Jun 26, 2024 $0.443 Jun 27, 2024
Full Dividend History

News

Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust

SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...

Other symbols: AAPYAMZPGOOPMSFYNFLP
5 weeks ago - Business Wire

Kurv Announces Special Distributions

SAN FRANCISCO--(BUSINESS WIRE)--Kurv Announces Special Distributions.

Other symbols: AAPYAMZPGOOPMSFYNFLP
4 months ago - Business Wire

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...

Other symbols: AZN
8 months ago - Business Wire